RxDoctor Payments DataLook up a doctor →

Paul Pockros, MD

Gastroenterology · la Jolla, CANPI 1124082748

Payments from drug & device makers

$1,538,521in general payments, 2019–2025

Across 762 payments — averaging $2019.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$1.1M
  • Gilead$291K
  • Intercept Pharma Europe Ltd.$75K
  • AbbVie$44K
  • Ipsen Biopharmaceuticals, Inc$32K
  • Novo Nordisk$20K
  • plus $26K from 31 others
$145in research payments, 2019–2025

Across 2 payments — averaging $72.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$145

What the payments were for

  • Consulting fees$92,47029%
  • Speaking & faculty fees$180,30157%
  • Grants$12,9604%
  • Travel & lodging$18,3166%
  • Food & beverage$13,5214%
  • Education$1310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,538,521 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$68,165
Medicare patients
310
Services billed
698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid49$457,572
LivdelziSeladelpar Lysine17$216,054
VemlidyTenofovir Alafenamide86$143,313
XifaxanRifaximin20$63,742
Ursodiol214$42,413
EliquisApixaban12$7,234
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates97$6,445
Azathioprine74$2,950
Entecavir19$1,319
Mycophenolate Mofetil13$861
Pantoprazole Sodium19$349
Omeprazole19$225
Spironolactone12$185
Prednisone24$168
Carvedilol19$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$1,052,172$457,57249 claims
GileadLivdelzi, Vemlidy$290,549$359,366103 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,304$63,74220 claims
PfizerEliquis$296$7,23412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →